Timing is Key: New Research Links Chemotherapy Effectiveness to Time of Day in Brain Cancer Treatment
A groundbreaking study reveals that the timing of chemotherapy administration may significantly impact its effectiveness in patients battling glioblastoma (GBM), an aggressive and often fatal form of brain cancer. The research, recently published in the Journal of Neuro-Oncology, suggests that aligning treatment with the body’s natural circadian rhythms could dramatically improve outcomes.
New insights into the biological mechanisms of GBM are offering a potential pathway to overcome the limitations of current treatments. Glioblastoma affects over 300,000 people globally each year, and despite advances in medical science, remains notoriously difficult to treat. The standard approach utilizes the chemotherapy drug temozolomide (TMZ), but tumors frequently develop resistance through a DNA repair enzyme called MGMT.
However, researchers have discovered that MGMT isn’t consistently active. Levels of both MGMT methylation – which effectively switches the gene “off” – and the amount of MGMT protein itself fluctuate throughout the day. This realization prompted an investigation into whether the time of a tumor biopsy could influence diagnostic results. A team at WashU Medicine provided five years of patient biopsy data, which researchers then analyzed.
“Methylation is currently used for diagnostic purposes in cancer, particularly for identifying brain tumors with varying molecular subtypes that are correlated with differences in treatment response,” explained a senior researcher involved in the study.
The core focus of the new research was to determine if these methylation levels remained stable or varied depending on the time of day. The findings were striking. “We found, repeatedly, an increased likelihood of morning biopsies being scored as methylated,” stated a lead investigator. This suggests that the timing of a biopsy could inadvertently influence a tumor’s diagnosis. “We are hopeful that this chronodiagnostic approach will help identify better ways to treat this devastating disease.”
These daily cycles in MGMT gene and protein expression also appear to regulate how sensitive tumors are to TMZ. Researchers observed that TMZ was more effective in the morning, leading them to hypothesize that this coincided with periods of lower MGMT activity, when the tumor’s repair mechanisms are less capable of counteracting the drug’s effects.
To delve deeper into this timing mechanism, a graduate student measured MGMT levels throughout the day in both tumor cells and patient samples. Collaborating with a mathematical biologist, they developed a predictive model to determine when TMZ would be most effective relative to the daily rhythm of MGMT.
“I love when math pushes us past intuition and helps us see something new,” remarked the math biologist. The model revealed that, given the time it takes for TMZ to inflict DNA damage and trigger cell death, administering the drug shortly after MGMT protein peaks provides the optimal window for action, while the tumor’s repair systems are at their weakest.
“My main takeaway from the modeling part of this work is that, while chronomedicine sounds simple in theory, figuring out what that right time is can be tough,” the biologist added. The ideal dosing time can be affected by numerous factors, including dosage and individual variations in circadian rhythms. “The good news is that math gives us a way to chop away at that complexity and get closer to answers that intuition alone can’t give us.”
The research team is optimistic that these findings could extend beyond TMZ, potentially improving the efficacy of other drugs that target similar biological pathways. They are also exploring the impact of time of day on other signals that either promote or suppress GBM growth, including dexamethasone, a drug commonly used to manage brain swelling. “It may be important to avoid treatment at times of day when it also promotes tumor growth,” a researcher noted.
This research was supported by grants from the National Institutes of Health and NCI, as well as funding from the Siteman Cancer Center, affiliated with Barnes-Jewish Hospital and WashU Medicine.
Source: Washington University in St. Louis.
